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Background: Major depressive disorder (MDD) is a serious, and common psychiatric disorder 
worldwide. By the year 2020, MDD will be the second cause of disability in the world. The 
GranadΣp study is the first, to the best of our knowledge, epidemiological study of mental 
disorders carried out in Andalusia (South Spain), being one of its main objectives to identify 
genetic and environmental risk factors for MDD and other major psychiatric disorders. In this 
study, we focused on the possible association of 91 candidate single nucleotide polymorphisms 
(SNPs) with MDD.
Methods: A total of 711 community-based individuals participated in the GranadΣp study. All 
individuals were extensively assessed for clinical, psychological, sociodemographic, life style, 
and other environmental variables. A biological sample was also collected for subsequent genetic 
analyses in 91 candidate SNPs for MDD. DSM-IV diagnosis of MDD was used as the outcome 
variable. Logistic regression analysis assuming an additive genetic model was performed to test 
the association between MDD and the genetic data. The experiment-wide significance threshold 
adjusted with the SNP spectral decomposition method provided a maximum P-value (8×10−3) 
required to identify an association. Haplotype analyses were also performed.
Results: One SNP (rs623580) located in the tryptophan hydroxylase 1 gene (TPH1; chromosome 
11), one intergenic variant (rs9526236) upstream of the 5-hydroxytryptamine receptor 2A 
gene (HTR2A; chromosome 13), and five polymorphisms (rs17689966, rs173365, rs7209436, 
rs110402, and rs242924) located in the corticotropin-releasing hormone receptor 1 gene (CRHR1; 
chromosome 17), all showed suggestive trends for association with MDD (P,0.05). Within 
CRHR1 gene, the TATGA haplotype combination was found to increase significantly the risk 
for MDD with an odds ratio =1.68 (95% CI: 1.16–2.42, P=0.006).
Conclusion: Although limited, perhaps due to insufficient sample size power, our results seem 
to support the notion that the hypothalamic–pituitary–adrenal and serotonergic systems are likely 
to be involved in the genetic susceptibility for MDD. Future studies, including larger samples, 
should be addressed for further validation and replication of the present findings.
Keywords: genetic association analysis, major depression, HPA axis, serotonergic system
Introduction
Major depression is the most common psychiatric disorder, with an estimated lifetime 
prevalence that varies from 8% to 12% across studies.1,2 It is a serious mental illness 
characterized by persistent sadness and anhedonia, as well as alterations in vegetative, 
psychomotor, and cognitive functions. It can deeply impair the person’s ability to 
function or cope with daily life, being a leading cause of disability worldwide.3
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Genetic factors clearly play a substantial role in the 
etiology of major depression, as evidenced by family and twin 
studies that report heritability estimates ranging from 17% to 
75%, with an average of 37%.4–6 Since major depression is 
responsible for a significant burden on our health systems,3 
the identification of underlying genetic factors has recently 
been recognized to be among the greatest challenges that 
researchers are facing.7 A better understanding of the genetic 
bases of major depression could provide us new insights into 
the etiology of such illness and lead to improved diagnosis, 
treatments, and prevention strategies.
Although several genome-wide association studies 
(GWAS)8 have been published in the last few years, none 
of them has robustly identified a locus that exceeds genome-
wide significance for major depressive disorder (MDD) or 
genetically related traits.8 The lack of conclusive results 
could be explained, at least, in part, by an underlying genetic 
vulnerability caused by the joint effect of multiple loci of 
small effect, difficult to detect from GWAS approaches.
In contrast to such results, some promising findings have 
been reported from classical genetic association studies. 
A recent review by Flint and Kendler8 shows that from almost 
200 candidate genes for MDD tested in different studies, only 
a few provided some robust results. This review also includes 
a meta-analysis focused on 26 of those candidate genes for 
MDD, of which seven yielded a significant P-value (SLC6A4, 
APOE, DRD4, GNB3, HTR1A, MTHFR, and SLC6A3).
Such suggestive results come from a neurobiologically 
informed strategy of genetic search (based on the existing 
knowledge of the underlying neural substrates of the dis-
order) which can be particularly informative in unraveling 
the genetic architecture of MDD. With this approach in the 
context of an epidemiological study on mental disorders with 
a representative sample of the province of Granada, southern 
Spain (the GranadΣp study), we designed a custom single 
nucleotide polymorphism (SNP) array containing 91 SNPs 
of relevance for MDD. The SNPs were chosen taking into 
account key candidate genes previously described in the 
literature, novel genes from putatively important pathways, 
and top hits from published GWAS on MDD. Our main aim 
was to evaluate the possible association of these 91 candidate 
SNPs with MDD.
Materials and methods
study context and design
The GranadΣp study is a cross-sectional epidemiological study 
based on a relatively large sample representative of the adult 
population living in the province of Granada (southern Spain). 
This study was designed to serve as a self-contained pilot study 
for a larger cross-sectional study using a sample of the entire 
Andalusia region (Plan Integral de Salud Mental en Andalucía 
epidemiological mental health study [PISMA-ep study]9), and 
both used the same assessment methods. Both studies were 
cross-sectional surveys aiming to establish the prevalence of 
major psychiatric disorders in Andalusia and to identify genetic 
and environmental risk factors for such conditions.
The recruitment of the sample took place between October 
2011 and December 2012 involving the province of Granada 
(n=711). All individuals in this study were randomly selected 
from the Andalusian Health Service users database, which is 
estimated to cover 98% of the population. Participants were 
assessed for clinical, psychological, sociodemographic, life 
style, and other environmental variables. Individuals who 
also agreed to participate in the genetic analysis gave specific 
informed consent and provided a biological sample. Partici-
pants were mostly Spanish of Spanish ancestry; although 
Spanish nationality was not an inclusion criterion and people 
coming from other European countries with European 
ancestry could also be included in the study.
The GranadΣp study was approved by the Research 
Ethic Committee of the University of Granada. The common 
methodology of both the GranadΣp and PISMA-ep studies 
has been described in more detail elsewhere.9
The sample
Sampling was performed in a two-stage cluster sampling 
with stratification of the primary sampling units depending 
on whether they were rural or urban. Rurality was deter-
mined according to the rurality of Andalusian municipalities 
index.10 The median of the rurality index for all Andalusian 
municipalities was taken into account to make the distinctions 
between rural and urban municipalities.
In the first stage, municipalities were sampled by prob-
ability proportional to size cluster sampling. Clusters were 
selected with proportional allocation within strata. The total 
number of selected municipalities represented approximately 
15% of the total of municipalities in the province of Granada. 
In the second stage, the individuals that made up the sample 
were selected using a simple random sampling procedure.
Eight hundred and nine noninstitutionalized community-
based participants living in the province of Granada agreed 
to take part in the survey. All interviews were performed 
between October 2011 and September 2012. To be able 
to estimate a 2% mental disorder prevalence with ±0.8% 
accuracy at a 95% confidence interval (CI) the sample was 
estimated at 1,176 participants.
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All living participants between the ages of 18 and 80 were 
selected for participation in the study, divided into four age 
groups. Exclusion criteria were: being outside the age range, 
having lived in Granada province for less than a year, not 
being able to communicate fluently in Spanish, being too 
ill to be able to complete the interview, having a diagnosis 
of dementia or mental retardation, living in an institution 
(hospital, prison, etc), having moved or not living normally 
at the address we had been given by the users database, and 
erroneous data from the users database (eg, an incomplete 
address). Excluded participants were replaced with other 
individual matched for age, sex, and location.
characterization of major depressive 
disorder
The Mini-International Neuropsychiatric Interview (MINI)11 
was used to ascertain psychiatric diagnoses in our sample. 
Interviews were conducted by professionally trained psy-
chologists and took place either in the participant’s local 
primary health care center or in their homes.
The psychiatric interview section was composed of the 
MINI interview that generates Axis I DSM-IV and ICD-10 
diagnoses for 16 mental disorders. This interview consists 
of one or two screening questions asked to all participants 
at the beginning of each of the diagnostic sections. Any 
participants responding positively to the screening questions 
are then asked the complete set of that section’s questions 
leading to ascertainment of that section’s specific diagnosis. 
Prevalence of MDD was calculated using the information 
from the MINI interview, where diagnoses of mental dis-
orders were determined by their answers about symptoms. 
A DSM-IV compatible diagnosis of MDD, generated from 




Ninety-one SNPs were selected for analysis in this study. 
These SNPs were chosen among the most replicated in pre-
vious genetic association studies on depression and among 
those described as suggestive or clearly associated with MDD 
in previous GWAS published between 2010 and 2011.12–18 We 
mined the public databases for general information about the 
genes and polymorphic variants of interest, including some 
haplotype tagging and potentially functional SNPs, as well 
as markers with minor allele frequencies .0.1. This informa-
tion was then combined and compared with the list of SNPs 
available from Illumina, Inc. (San Diego, CA, USA).
genotyping
A biological sample was obtained from each participant 
using the Oragene DNA saliva collection kit (OG-500; DNA 
Genotek Inc, Ottawa, ON, Canada). DNA extraction was 
performed by using standard procedures. DNA concentra-
tion was measured by absorbance using the Infinite® M200 
PRO multimode reader (Tecan US Inc, Research Triangle 
Park, NC, USA).
Genotyping was performed using TaqMan® OpenArray™ 
Genotyping System (Thermo Fisher Scientific, Waltham, 
MA, USA) following the manufacturer’s instructions. Raw 
data were analyzed with the TaqMan® Genotyper v1.2 
software (Thermo Fisher Scientific).
Stringent quality control criteria were applied to both 
SNP and individual data. SNPs were excluded if they had a 
missing genotype rate higher than 1% or showed departure 
from the Hardy–Weinberg equilibrium (P,0.01). Individuals 
with genotypic data showing a missing rate .10% or those 
with a non-European ancestry were also excluded.
After quality control procedures, 85 SNPs and 567 
individuals were finally included in the analyses. Detailed 
information about those SNPs, such as location, function, or 
possible allelic variants, is given in Table S1.
statistical analysis
The Hardy–Weinberg equilibrium was checked in the entire 
sample, and both in depressed individuals and controls, by 
using Plink (http://pngu.mgh.harvard.edu/~purcell/plink/).19
The same statistical package was also used to test the 
association between MDD and the SNP data assuming an 
additive genetic model.
The number of effective-independent tests performed was 
calculated with the single nucleotide polymorphism spectral 
decomposition (SNPSpD) method. This method corrects for 
nonindependence of SNPs in linkage disequilibrium (LD) with 
each other.20 Under this method, the effective number of indepen-
dent marker loci was 61, and the experiment-wide significance 
threshold required to keep type I error rate at 5% was 8×10−3.
We further estimated the haplotype frequencies with 
the standard expectation–maximization algorithm and per-
formed simple tests of association based on the distribution 
of probabilistically inferred set of haplotypes in depressed 
individuals and controls.
Haplotype-specific odds ratio (OR) and 95% CI were 
calculated. Statistical significance was set at P,0.05 for 
haplotype association analysis.
Statistical power was calculated by using the software 
QUANTO v.1.2.4 (http://biostats.usc.edu/Quanto.html). 





QUANTO allowed us to calculate both the effect size we 
could detect (OR ranging from 2 to 5) and the power we 
had (ranging from 50% to 80% with a P,8×10−3) taking 
into account: i) our sample size (65 cases and 505 controls); 
ii) the prevalence of the illness (15%); iii) the frequency of 




Out of 1,176 community-based individuals who were 
approached and invited to take part in this study, 711 partici-
pants (305 men and 406 women; mean age ± SD: 49.7±16.7) 
provided written informed consent and donated a biological 
sample. The final study sample included 567 individuals 
(Figure 1), 67 (11.8%) participants fulfilled criteria for MDD 
(25 men, 42 women; mean age ± SD: 51.25±14.64), and 
500 were controls (230 men, 270 women; mean age ± SD: 
49.34±17.05). The control group did not have diagnosis of 
any Axis I-DSM-IV psychiatric disorder. Sociodemographic 
and clinical characteristics of the sample are summarized in 
Table 1. In brief, 312 (55%) were women; mean age was 
49.6 years (SD=16.8) ranging from 19 to 83; more than half 
the participants lived in urban areas; most were educated at 
least to secondary school level, were in some sort of stable 
relationship, and were unemployed (Table 1).
Participants who agreed to take part in the genetic study 
did not vary significantly from those who refused to give 
a genetic sample in terms of sex (female 57.1% vs 54.7%, 
χ2=0.14, P=0.71), mean age (49.72 vs 52.09 years, Student’s 
t=0.57, P=0.45), living area (χ2=3.87, P=0.14), education 
(χ2=7.64, P=0.27), marital status (χ2=2.33, P=0.68), working 
status (χ2=4.10, P=0.54), or prevalence of DSM-IV MDD 
(10.5% vs 9.4%, χ2=0.09, P=0.77).
genetic association analysis
Genotype frequencies were found to be in Hardy–Weinberg 
equilibrium in the whole sample, and both in cases and con-
trols (P.0.05 in all cases).
None of the 85 SNPs were significantly associated with 
MDD after multiple testing correction (P.8×10−3 in all 
comparisons). However, one SNP (rs623580) located in the 
tryptophan hydroxylase 1 gene (TPH1; chromosome 11), 
one intergenic variant (rs9526236) between the esterase 
D gene (ESD) and the 5-hydroxytryptamine receptor 2A 
gene (HTR2A; chromosome 13), and five polymorphisms 
(rs17689966, rs173365, rs7209436, rs110402, and rs242924) 
located in the corticotropin-releasing hormone receptor 1 
gene (CRHR1; chromosome 17), all showed suggestive 
trends for association with MDD, reaching traditionally 
conventional levels of statistical significance (P,0.05).
Detailed association results for these seven SNPs are 
shown in Table 2. Figure 2 and Table S1 show the association 
results of the 85 SNPs included in the analyses.
haplotype analysis
A five-marker haplotype analysis was performed including 
the five CRHR1 SNPs univariantly associated with MDD. 
Table 3 shows haplotype frequencies both in cases and 
controls. Among all the possible haplotype combinations, 
Figure 1 granad∑p study sample and response rates.
Abbreviation: Qc, quality control.
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three of them accounted for more than 96% of the total 
variability observed both in depressive cases and controls. 
However, these haplotypes were not equally distributed 
in both groups (χ2=8.70, df=3, P=0.034). Particularly, 
the haplotype TATGA (rs7209436–rs110402–rs242924–
rs173365–rs17689966) was found to be over-represented 
in MDD cases (42%) when compared with controls (30%) 
(OR=1.68; 95% CI: 1.16–2.43; P=0.005) (Table 3).
A three-marker haplotype analysis was also performed 
including only the three SNPs that constitute the known 
CRHR1 TAT haplotype (which involves the following SNPs: 
rs7209436–rs110402–rs242924; Table 3). Such a haplotype 
combination (inserted in the five-SNPs haplotype described) 
has previously been described as a risk haplotype for depres-
sion in other studies.21–24
In our sample, the haplotype TAT was also more frequent 
in MDD cases (44%) than in controls (34%) (OR=1.53; 95% 
CI: 1.06–2.20; P=0.023), whereas the haplotype CGG was 
significantly more frequent in controls (65%) than in MDD 
cases (44%) (OR=0.66; 95% CI: 0.46–0.96; P=0.028).
Discussion
Despite significant advances in the search of the genetic 
basis of MDD, knowledge of the specific genes involved, 
genetic mechanisms, and physiological intermediates under-
lying the origin of such illness remains still very limited. 
Table 1 Sociodemographic and clinical profile of the GranadΣp sample
Variable Frequency
Whole sample (N=567) Cases (n=67) Controls (n=500)
sex (male/female) 255 (45%)/312 (55%) 25 (37.3%)/42 (62.7%) 230 (46%)/270 (54%)
Mean age 49.6 years (sD 16.8) 51.3 years (sD 14.6) 49.3 years (sD 17.1)
living area
Urban 348 (61.4%) 40 (59.7%) 308 (61.6%)
intermediate 162 (28.5%) 18 (26.9%) 144 (28.8%)
rural 57 (10.1%) 9 (13.4%) 48 (9.6%)
education
illiterate 102 (18%) 17 (25.4%) 85 (17%)
Primary 215 (37.9%) 29 (43.3%) 186 (37.2%)
secondary or higher 250 (44.1%) 21 (31.3%) 229 (45.8%)
Marital status
single 84 (14.8%) 6 (9%) 78 (15.6%)
Married/couple 420 (74.1%) 47 (70.1%) 373 (74.6%)
Widowed 35 (6.2%) 7 (10.4%) 28 (5.6%)
Divorced/separated 28 (4.9%) 7 (10.5%) 21 (4.2%)
Working status
employed 225 (39.7%) 20 (29.9%) 205 (41%)
Unemployed 115 (20.3%) 18 (26.9%) 97 (19.4%)
retired 99 (17.4%) 13 (19.4%) 86 (17.2%)
incapacitated for work 17 (3%) 6 (9%) 11 (2.2%)
Family or household care 80 (14.1%) 9 (13.4%) 71 (14.2%)
Full-time student 31 (5.5%) 1 (1.5%) 30 (6%)
Table 2 single marker association analyses between the top seven risk sNPs and MDD in the granadΣp study




rs623580 TPH1 11 18042430 a/T 0.37 (a) 0.614 0.219 0.026
rs9526236 intergenic variant 13 46814392 c/T 0.42 (T) 0.657 0.189 0.027
rs17689966 CRHR1 17 45833089 g/a 0.39 (g) 1.524 0.190 0.026
rs173365 CRHR1 17 45823708 a/g 0.37 (a) 1.526 0.192 0.027
rs7209436 CRHR1 17 45792776 c/T 0.47 (c) 1.540 0.188 0.022
rs110402 CRHR1 17 45802681 g/a 0.46 (g) 1.487 0.190 0.036
rs242924 CRHR1 17 45808001 g/T 0.46 (g) 1.502 0.191 0.033
Notes: arisk alleles are underlined; bminor allele is in parentheses.
Abbreviations: chr, chromosome; MaF, minor allele frequency; MDD, major depressive disorder; Or, odds ratio; se, standard error; sNPs, single nucleotide 
polymorphisms.





Candidate gene studies, mostly focused on genes involved 
in neurotransmitter circuits or in reactions to stress, have 
yielded some suggestive results, although not conclusive 
enough. One of the reasons could be the polygenic nature 
of the illness and the hypothetically large number of loci 
involved, each of small effect. Moreover, as reported in Maier 
et al,25 MDD seems to be less homogeneous across popula-
tions than other psychiatric disorders such as schizophrenia 
and bipolar disorder. Replication studies in independent 
samples are absolutely necessary to test the robustness of 
such association reports.
In this study, we aimed to replicate previously reported 
associations between candidate genes and MDD26–29 in a 
sample of the general adult population of Andalusia (South of 
Spain). Although none of the associations tested were statisti-
cally significant after multiple testing correction (P.8×10−3), 
seven SNPs in three candidate genes (TPH1, HTR2A, and 
CRHR1) showed trends toward association (P,0.05), and 
one haplotype combination at CRHR1 was found to increase 
significantly the risk for MDD in our sample.
association of two key serotonergic 
pathway genes (TPH1 and HTR2A) with 
MDD
TPH1 and HTR2A are key genes in the serotonergic 
neurotransmission. Disturbances in the serotonin (5- 
hydroxytryptamine, 5-HT) system constitute the neurobio-
logical abnormality most extensively studied and consistently 
associated with MDD.30,31 The neurotransmitter serotonin 
modulates various functions related to homeostasis and 
responses to the environment, which in turn are linked to 
MDD. In addition, most antidepressants have a direct or 
indirect influence on serotonergic activity.32,33 Several lines 
of evidence suggest that abnormalities in the functioning of 
the serotonergic system are present in psychiatric conditions 
such as depression, schizophrenia, and obsessive compulsive 
disorders, as well as suicide and aggression.34
TPH1 gene encodes a tryptophan hydroxylase (TPH) 
isoform, a rate-limiting enzyme involved in the synthesis of 
neurotransmitter serotonin.32,35 Although TPH gene sequence 
variants and multiple psychiatric disorders have been asso-
ciated over time, most mutations are found in noncoding 
regions of the gene, and limited information about their 
functional consequences is available. The administration of 
tryptophan and subsequent stimulation of serotonin produc-
tion has an antidepressant effect, whereas the inhibition of 
TPH may precipitate depression.34 In 2002, Kim et al found 
that TPH expression is upregulated by chronic treatment 
Figure 2 Manhattan plot displaying association results between the 85 sNPs and MDD.
Note: Dotted lines represent the P-value 0.05 and 0.001 thresholds.
Abbreviations: chr, chromosome; MDD, major depressive disorder; sNPs, single nucleotide polymorphisms.






χ2 P-value OR (95% CI)b
TATGA 0.42 0.30 7.92 0.005 1.68 (1.16–2.42)
cggga 0.15 0.16 0.14 0.705
TaTag 0.02 0.04 1.48 0.224
cggag 0.41 0.50 3.38 0.066
TAT 0.44 0.34 5.18 0.023 1.53 (1.06–2.20)
caT 0.01 0.01 0.32 0.573
CGG 0.55 0.65 4.53 0.033 0.66 (0.46–0.96)
Notes: asNPs forming the haplotypes are 1) rs7209436–rs110402–rs242924–rs 
173365–rs17689966, and 2) rs7209436–rs110402–rs242924; bodds ratio (95% ci) 
associated with TaTga, TaT, and cgg haplotypes compared with any other 
haplotype combination. Bold entries indicate that the haplotypes are significantly 
more frequent in MDD cases than in controls or vice versa.
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio.




hPa and serotonin genes may modulate risk for major depression
with selective serotonin reuptake inhibitors, which provide 
an additional link between the antidepressant effect and 
TPH activity.36
The rs623580 (3804T/A) is an upstream genetic variant 
located in a regulatory region within the 5′-UTR of the TPH1 
gene at chromosome 11.37 Previous studies involving this 
polymorphism have reported the negative results with affec-
tive disorders37,38 and suicide-related behavior.39 However, 
Kwak et al40 in a GWAS of 8,842 individuals found that 
this polymorphism was associated with body mass index, a 
measure of obesity many times related to MDD.41–44
There is a large amount of data implicating the serotonin 
system in the pathophysiology of affective disorders, but 
much of the attention is given specifically to genes coding 
for serotonin receptors and transporters.32,26 Moreover, almost 
every compound ever synthesized in order to inhibit sero-
tonin reuptake has been proved to be a clinically effective 
antidepressant.45 The HTR2A is particularly relevant in the 
field of biological psychiatry due to its role as an important 
target for psychotropic drugs and its altered expression 
in several neuropsychiatric disorders such as MDD and 
schizophrenia.26,46,47 HTR2A gene in chromosome 13 is impli-
cated in the regulation of serotonergic neurotransmission48 and 
the hypothalamic–pituitary–adrenal (HPA) axis.49,50 HTR2A 
has been extensively studied in genetic association studies of 
many psychiatric conditions, but the results are inconclusive 
and do not allow us to draw any definite conclusion about the 
potential implication of the HTR2A gene in MDD.51
In our study, the rs9526236 polymorphism (HTR2A) 
showed a trend for association with MDD. Although it 
has not been investigated in previous studies, its location 
upstream of the promoter region of HTR2A gene and its 
potential functionality makes it a good candidate variant to 
be further investigated in future studies given that both MDD 
and some antidepressants effects are linked to functionality 
of 5HT2A receptors.
association between CRHR1 and MDD
CRHR1 encodes a G-protein-coupled receptor that binds 
neuropeptides of the corticotropin-releasing hormone (CRH) 
family that are major regulators of the HPA pathway.52 
The encoded protein is essential for the activation of signal 
transduction pathways that regulate diverse physiological 
processes including stress, reproduction, immune response, 
and obesity.53
In response to stressful events, this receptor modifies the 
extent and duration of the response mediating the action of 
CRH on the pituitary gland to secrete corticotropin into the 
bloodstream. Corticotropin stimulates the production of cor-
tisol in the adrenal cortex.24 According to the hypothalamic–
pituitary–cortisol hypothesis of depression, abnormalities in 
the cortisol response to stress may underlie depression.45
In this study, we have found five SNPs (rs7209436, 
rs110402, rs242924, rs173365, and rs17689966) within 
CRHR1 gene suggestive of being associated with MDD. 
The haplotype analysis (including these five CRHR1 
markers) revealed significant differences in the distribu-
tion of haplotype combinations between cases and controls. 
Particularly, TATGA haplotype (rs7209436–rs110402–
rs242924–rs173365–rs17689966) was found in our sample 
to be significantly more frequent in cases with MDD than in 
controls (42% vs 30%, P=0.006).
Several SNPs at CRHR1 locus have been associated with 
the origin of MDD in previous studies.54,55 Some authors sug-
gest that variation at CRHR1 could modulate reactivity to 
stress, and that altered CRHR1 function would be associated 
with stress-related psychopathology, particularly anxiety, and 
depressive disorders.56
CRHR1 haplotypes have also been associated with 
MDD,54,55 as well as with MDD mediated by childhood 
trauma21,24 and clinical response to antidepressant treatment.54,57 
Our results are in agreement with these previous reports and, 
although our power is limited by our sample size, our data 
are in congruence with the pivotal neurobiological role that 
CRHR1 seems to play in the regulation of emotions. No 
doubt, CRHR1 is a highly suggestive candidate gene for MDD 
which would deserve further attention in future analysis.
Taking all together, our results are in agreement with 
previous neurochemical findings reporting disturbances 
at both HPA and serotonergic systems as highly likely 
implicated in MDD. Although a full comprehension of the 
nature of the relationships existing between both (HPA and 
serotonergic) systems is yet needed, it is well known that the 
HPA axis functioning can be modulated by various neuronal 
signaling molecules, including serotonin58 and, conversely, 
serotonergic activity can be modulated by HPA axis (ie, CNS 
concentrations of serotonin can decrease after a stimulation 
of the tryptophan metabolism induced by glucocorticoids).59 
Since such relationship exists, we could think that TPH1, 
HTR2A, and CRHR1 genes work synergistically and they 
jointly contribute to confer a genetic risk profile for MDD 
which may differ according to the specific allele combina-
tions carried by each subject. This hypothesis has not been 
tested in our study as our sample has a limited size but, in 
future studies, it would be desirable to analyze the possible 
joint effect of TPH1, HTR2A, and CRHR1 genes on MDD.






One of the main strengths of our study is its design, based on 
a candidate gene approach. Candidate gene studies are rela-
tively low-cost and quick to perform, are focused on previous 
knowledge related to the genes and mechanisms underlying 
the etiology of the disease, and involve a relatively small 
number of statistical tests in comparison with traditional 
GWAS, so that the significance threshold can be less strin-
gent.60 Another strength of our study is that the sample is rep-
resentative of the general population and considerably well 
characterized for clinical, psychological, sociodemographic, 
life style, and environmental variables. No potential problems 
of population stratification are expected as the sample comes 
from a homogeneous ethnic background, being all individuals 
Caucasian of Spanish ancestry. The main limitation of our 
study is its sample size which has a limited power to detect 
small and even moderate effects, as the power calculation 
performed in the statistics section reveals. A reduced number 
of candidate SNPs have also been investigated for this study. 
However, we prioritized theory-driven replication of previ-
ous associations between key genes and MDD, other genes 
from putatively important pathways (genes already known 
or even novel genes identified in recent GWAS) might not 
have been included in the analysis.
Conclusion
In conclusion, our results support that the HPA and sero-
tonergic neurotransmission variability are both likely to be 
involved in the genetic susceptibility for MDD. This is in 
agreement with neurochemical findings which report dis-
turbances at both HPA and serotonergic systems as highly 
likely implicated in MDD, although a full comprehension of 
the nature of such relationships is yet needed. Future studies 
including larger samples will be needed for further validation 
and replication of the present findings.
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Supplementary material
Table S1 association analyses between the 85 sNPs and MDD in the granadΣp study
Chr Gene SNP Description MDD
OR SE P-value
1 RPL31P12 rs2568958 ribosomal protein l31 pseudo-gene 12 0.746 0.208 0.157
– rs2815752 intergenic variant 0.840 0.208 0.401
TNNI3K/FPGT-TNNI3K rs1514175 TNNi3 interacting kinase/FPgT-TNNi3K read through 1.113 0.188 0.568
SEC16B rs543874 sec16 homolog B (Saccharomyces cerevisiae) 1.344 0.269 0.272
2 – rs713586 intergenic variant 0.943 0.185 0.752
3 TRIM71 rs1878887 Tripartite motif containing 71, e3 ubiquitin protein ligase 1.339 0.234 0.212
DGKG rs9816226 Diacylglycerol kinase, gamma 90 kDa 0.821 0.258 0.446
4 – rs10938397 intergenic variant 0.802 0.190 0.246
5 RP11-158J3.2/HTR1A rs6295 gene rP11-158J3.2/5-hydroxytryptamine (serotonin) 
receptor 1a, g-protein-coupled
0.851 0.191 0.395
6 FKBP5 rs992105 FK506 binding protein 5 0.829 0.259 0.468
rs1360780 0.821 0.205 0.337
FKBP5/RP3-340B19.5 rs737054 FK506 binding protein 5/gene rP3-340B19.5 1.258 0.209 0.273
rs3777747 1.326 0.188 0.134
KHDC1/RP11-257K9.8 rs2350753 Kh homology domain containing 1/uncharacterized 
protein
0.980 0.310 0.948
– rs4235835 intergenic variant 1.347 0.193 0.123
7 CRHR2 rs3779250 corticotropin-releasing hormone receptor 2 0.952 0.188 0.795
rs2267710 1.102 0.192 0.613
rs1076292 1.083 0.188 0.673
rs2284217 1.290 0.221 0.248
9 – rs7866605 intergenic variant 3.028 0.847 0.191
NTRK2 rs1211166 Neurotrophic tyrosine kinase, receptor, type 2 0.946 0.244 0.819
11 TPH1 rs10488683 Tryptophan hydroxylase 1 0.882 0.184 0.494
rs211107 1.262 0.184 0.206
rs623580 0.614 0.219 0.026
rs652458 1.250 0.185 0.228
– rs7110238 intergenic variant 0.877 0.189 0.486
– rs11024460 intergenic variant 0.945 0.209 0.786
SAAL1 rs951624 serum amyloid a-like 1 1.455 0.327 0.252
BDNF/BDNF-AS rs6265 Brain-derived neurotrophic factor (BDNF)/BDNF 
antisense rNa
0.955 0.240 0.847
RP11-587D21.4/BDNF rs10767664 gene rP11-587D21.4/Brain-derived neurotrophic factor 0.900 0.226 0.640
MTCH2 rs3817334 Mitochondrial carrier 2 0.839 0.209 0.401
12 TBC1D15 rs3759171 TBc1 domain family, member 15 1.003 0.203 0.989
rs10506643 0.843 0.330 0.604
TPH2 rs2129575 Tryptophan hydroxylase 2 0.948 0.246 0.829
rs1386493 1.102 0.241 0.687
rs6582078 0.940 0.188 0.741
rs1386497 0.846 0.273 0.540
rs1487278 0.979 0.238 0.930
rs1386482 1.299 0.198 0.187
rs1872824 0.988 0.196 0.952
13 – rs9526236 intergenic variant 0.657 0.189 0.027
HTR2A rs3125 5-hydroxytryptamine (serotonin) receptor 2a, 
g-protein-coupled
1.056 0.239 0.820
rs6314 0.871 0.344 0.688
rs977003 1.366 0.183 0.088
rs9567735 1.221 0.243 0.411
rs582385 1.276 0.233 0.296
rs731779 0.595 0.280 0.064
rs9534505 0.722 0.376 0.386
rs2070037 0.743 0.244 0.222
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Chr Gene SNP Description MDD
OR SE P-value
rs6311 0.944 0.183 0.754
rs1328685 0.902 0.288 0.720
HTR2A/HTR2A-AS1 rs7330636 5-hydroxytryptamine (serotonin) receptor 2a, 
g-protein-coupled/hTr2a antisense rNa 1
1.257 0.193 0.236
rs2296972 0.899 0.223 0.634
rs659734 1.365 0.344 0.366
– rs2149434 regulatory region variant 1.013 0.196 0.946
– rs943903 intergenic variant 1.014 0.196 0.944
15 MAP2K5 rs2241423 Mitogen-activated protein kinase kinase 5 1.117 0.211 0.601
16 – rs12444979 intergenic variant 0.957 0.281 0.877
SH2B1 rs7498665 sh2B adaptor protein 1 0.968 0.199 0.872
ATP2A1/SH2B1 rs7359397 aTPase, ca2+ transporting, cardiac muscle, fast twitch  
1/sh2B adaptor protein 1
0.916 0.201 0.661
17 CRHR1/RP11-105N13 rs12953076 corticotropin-releasing hormone receptor 1/gene 
rP11-105N13
0.942 0.229 0.794
rs4076452 0.944 0.230 0.801
rs12942300 0.653 0.322 0.186
rs7209436 1.540 0.188 0.022
rs4792887 0.944 0.284 0.838
rs110402 1.487 0.190 0.036
rs242924 1.502 0.191 0.033
rs242939 0.691 0.372 0.320
CRHR1 rs173365 corticotropin-releasing hormone receptor 1 1.526 0.192 0.027
rs1396862 0.895 0.212 0.601
rs1876831 0.911 0.186 0.616
rs17689966 1.524 0.190 0.026
rs1876828 1.034 0.201 0.866
18 – rs17782313 intergenic variant 1.207 0.220 0.392
19 QPCTL rs2287019 glutaminyl-peptide cyclotransferase-like 0.952 0.242 0.840
22 COMT/MIR4761 rs4680 catechol-O-methyltransferase/microrNa 4761 1.040 0.195 0.839
X HTR2C rs508865 5-hydroxytryptamine (serotonin) receptor 2c, 
g-protein-coupled
1.333 0.217 0.184
rs505971 1.336 0.217 0.182
rs12858300 1.484 0.396 0.319
rs12688102 1.210 0.219 0.384
rs12833104 0.873 0.305 0.655
rs6318 1.468 0.260 0.140
rs2428712 1.445 0.266 0.167
rs5946018 1.477 0.263 0.137
rs1801412 1.650 0.400 0.211
Note: – indicates the specific SNP is not located in a gene, it is an intergenic variant. 
Abbreviations: chr, chromosome; MDD, major depressive disorder; Or, odds ratio; se, standard error; sNP, single nucleotide polymorphism.
